IntoCell Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Daejeon South Korea

Primary Industry

Pharmaceuticals

About

Founded in 2015 and based in Daejeon, South Korea, IntoCell operates as a researcher and developer of anti-cancer drugs that utilize linker technology that eliminates cancer cells in the human body. In February 2016, Intocell raised KRW 6 billion in venture funding from new investors Atinum Investment, KNet Investment Partners, Partners Investment, Seoul Investment Partners, and Stonebridge Capital.

Current Investors

Atinum Investment, Seoul Investment Partners, Stonebridge Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.intocell.co.kr

Company Stage

Series C

Total Amount Raised

Subscriber access only

Timeline of Key Events

Want to see the Timeline of Key Events?

Request a demo for full access to this profile.

Employee Data

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.